Amicus follows Sanofi with disappointing pivotal Pompe data, casting further doubt on approvals.
Toxicity worries send yet another Gilead/Galapagos project, ziritaxestat, to the scrapheap.
Immunovant and other FcRn-players must hope that a potential safety signal turns out to be indication rather than class specific.
Merck & Co’s move illustrates how hard it will be for the second wave of Covid-19 vaccine candidates to succeed.
Bintrafusp alfa’s most important study, head to head against Keytruda in front-line lung cancer, is scrapped.
The vast majority of industry-sponsored studies suspended because of Covid-19 resumed quickly, a new analysis finds.
Troriluzole has failed in an Alzheimer’s trial, reminding the markets that this is par for the course in this disease.